Abstract
A recent study reported a detrimental effect of phosphodiesterase type 5 inhibitors (PDE5-Is) on biochemical recurrence (BCR) after radical prostatectomy (RP) for prostate cancer (PCa). We tested the association between PDE5-I use, PDE5-I therapy scheme, number of PDE5-I pills taken, and BCR in 2579 patients treated with bilateral nerve-sparing RP for PCa between 2004 and 2013 at a single center. Patients were categorized according to PDE5-I use within 2 yr after surgery as on demand, rehabilitation schedule (daily PDE5-I use for at least 3 mo), and no PDE5-I use. Multivariable (MVA) Cox regression models tested the association between PDE5-I and BCR. The same analyses were repeated using the number of PDE5-I pills taken by each patient. Overall, 674 patients (26.1%) received PDE5-Is. At MVA analysis, PDE5-I use, type of administration schedule, and number of PDE5-I pills were not significantly associated with higher risk of BCR (all p ≥ 0.2) after accounting for multiple confounders including time from RP to PDE5-I use. While awaiting further studies, patients should not be denied PDE5-I treatment after RP. Patient summary Among patients treated with radical prostatectomy, phosphodiesterase type 5 inhibitor use was not associated with an increased risk of biochemical recurrence, regardless of the therapeutic regimen used.
| Original language | English |
|---|---|
| Pages (from-to) | 750-753 |
| Number of pages | 4 |
| Journal | European Urology |
| Volume | 68 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - Nov 1 2015 |
Fingerprint
Keywords
- Biochemical recurrence
- Phosphodiesterase type 5 inhibitors
- Prostate cancer
- Radical prostatectomy
ASJC Scopus subject areas
- Urology
Cite this
A detailed analysis of the association between postoperative phosphodiesterase type 5 inhibitor use and the risk of biochemical recurrence after radical prostatectomy. / Gallina, Andrea; Bianchi, Marco; Gandaglia, Giorgio; Cucchiara, Vito; Suardi, Nazareno; Montorsi, Francesco; Briganti, Alberto.
In: European Urology, Vol. 68, No. 5, 01.11.2015, p. 750-753.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A detailed analysis of the association between postoperative phosphodiesterase type 5 inhibitor use and the risk of biochemical recurrence after radical prostatectomy
AU - Gallina, Andrea
AU - Bianchi, Marco
AU - Gandaglia, Giorgio
AU - Cucchiara, Vito
AU - Suardi, Nazareno
AU - Montorsi, Francesco
AU - Briganti, Alberto
PY - 2015/11/1
Y1 - 2015/11/1
N2 - A recent study reported a detrimental effect of phosphodiesterase type 5 inhibitors (PDE5-Is) on biochemical recurrence (BCR) after radical prostatectomy (RP) for prostate cancer (PCa). We tested the association between PDE5-I use, PDE5-I therapy scheme, number of PDE5-I pills taken, and BCR in 2579 patients treated with bilateral nerve-sparing RP for PCa between 2004 and 2013 at a single center. Patients were categorized according to PDE5-I use within 2 yr after surgery as on demand, rehabilitation schedule (daily PDE5-I use for at least 3 mo), and no PDE5-I use. Multivariable (MVA) Cox regression models tested the association between PDE5-I and BCR. The same analyses were repeated using the number of PDE5-I pills taken by each patient. Overall, 674 patients (26.1%) received PDE5-Is. At MVA analysis, PDE5-I use, type of administration schedule, and number of PDE5-I pills were not significantly associated with higher risk of BCR (all p ≥ 0.2) after accounting for multiple confounders including time from RP to PDE5-I use. While awaiting further studies, patients should not be denied PDE5-I treatment after RP. Patient summary Among patients treated with radical prostatectomy, phosphodiesterase type 5 inhibitor use was not associated with an increased risk of biochemical recurrence, regardless of the therapeutic regimen used.
AB - A recent study reported a detrimental effect of phosphodiesterase type 5 inhibitors (PDE5-Is) on biochemical recurrence (BCR) after radical prostatectomy (RP) for prostate cancer (PCa). We tested the association between PDE5-I use, PDE5-I therapy scheme, number of PDE5-I pills taken, and BCR in 2579 patients treated with bilateral nerve-sparing RP for PCa between 2004 and 2013 at a single center. Patients were categorized according to PDE5-I use within 2 yr after surgery as on demand, rehabilitation schedule (daily PDE5-I use for at least 3 mo), and no PDE5-I use. Multivariable (MVA) Cox regression models tested the association between PDE5-I and BCR. The same analyses were repeated using the number of PDE5-I pills taken by each patient. Overall, 674 patients (26.1%) received PDE5-Is. At MVA analysis, PDE5-I use, type of administration schedule, and number of PDE5-I pills were not significantly associated with higher risk of BCR (all p ≥ 0.2) after accounting for multiple confounders including time from RP to PDE5-I use. While awaiting further studies, patients should not be denied PDE5-I treatment after RP. Patient summary Among patients treated with radical prostatectomy, phosphodiesterase type 5 inhibitor use was not associated with an increased risk of biochemical recurrence, regardless of the therapeutic regimen used.
KW - Biochemical recurrence
KW - Phosphodiesterase type 5 inhibitors
KW - Prostate cancer
KW - Radical prostatectomy
UR - http://www.scopus.com/inward/record.url?scp=84942983100&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942983100&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2015.02.002
DO - 10.1016/j.eururo.2015.02.002
M3 - Article
C2 - 25700565
AN - SCOPUS:84942983100
VL - 68
SP - 750
EP - 753
JO - European Urology
JF - European Urology
SN - 0302-2838
IS - 5
ER -